{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.4","upperLimit":"78.3","value":"60.0"},{"groupId":"OG001","lowerLimit":"30.4","upperLimit":"85.0","value":"60.0"},{"groupId":"OG002","lowerLimit":"1.0","upperLimit":"65.7","value":"20.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Per International Myeloma Working Group criteria, complete response (CR): negative immunofixation of serum and urine, normalization of free light chain (FLC) ratio if at study entry FLC was only measurable non-bone parameter, \\<5% plasma cells in bone marrow, disappearance of any soft tissue plasma cytomas; stringent complete response (sCR): all of above, + normal serum FLC ratio in all patients and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; partial response (PR): \\>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\< 200 mg per 24 hours, \\>=50% decrease in difference between involved and uninvolved FLC levels or a 50% decrease in level of involved FLC with 50% decrease in ratio, \\>=50% reduction in bone marrow plasma cells, if baseline percentage was \\>=30%, \\>=50% reduction in size of soft tissue plasmacytoma; very good partial response (VGPR): PR + improvements in serum and urine M-components","dispersionType":"90% Confidence Interval","groups":[{"description":"Lenalidomide at 25 mg/day days 1-21 and Dexamethasone 40 mg days 1, 8, 15 and 22 every 28 days.","id":"OG000","title":"Group A CrCl 30-60 mL/Min"},{"description":"Lenalidomide at 25 mg/day days 1-21 and Dexamethasone 40 mg days 1, 8, 15 and 22 every 28 days.","id":"OG001","title":"Group B CrCL<30 mL/Min, Not on Dialysis"},{"description":"Lenalidomide at 25 mg/day for days 1-21 and Dexamethasone 40 mg days 1, 8, 15 and 22 every 28 days.","id":"OG002","title":"Group C CrCL<30 mL/Min and on Dialysis"}],"paramType":"NUMBER","populationDescription":"Patients treated at the recommended phase II dose","reportingStatus":"POSTED","timeFrame":"56 months","title":"Percentage of Participants Who Experience a Response [sCR, CR, VGPR, PR]","type":"PRIMARY","unitOfMeasure":"percentage of participants"}